Skip to main content
. 2023 Apr 17;12(8):e029565. doi: 10.1161/JAHA.122.029565

Figure 1. Patient populations evaluated for the renoprotective effects of ARNIs in major RCTs.

Figure 1

Boxes with light blue background described in red letters are populations for which there is insufficient evidence on ARNI treatment to date. ARNI indicates angiotensin receptor‐neprilysin inhibitor; EF, ejection fraction; GFR, glomerular filtration rate; HF, heart failure; PARADIGM‐HF, Prospective Comparison of ARNI With ACEI [Angiotensin‐Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure; PARAGON‐HF, Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction; RCT, randomized controlled trial; UACR, urinary albumin/creatinine ratio; and UK HARP‐III, United Kingdom Heart and Renal Protection‐III.